Quantcast

Latest Hypophosphatasia Stories

2014-04-15 14:45:09

The International and American Associations for Dental Research (IADR/AADR) have published a paper titled "Rare Bone Diseases and Their Dental, Oral, and Craniofacial Manifestations." The complete review by researchers Sunday O. Akintoye, Andrea B. Burke, Alison M. Boyce, Michael Collins, Brian L. Foster, Rachel I. Gafni, Janice S. Lee, Mary Scott Ramnitz, Martha J. Somerman and J. Timothy Wright is published in the OnlineFirst portion of the IADR/AADR Journal of Dental Research (JDR)....

2012-03-08 13:42:25

Doctors at Washington University School of Medicine in St. Louis, working with Shriners Hospital for Children and other institutions, have identified a promising new treatment for a rare and sometimes life-threatening bone disorder that can affect infants and young children. Known as hypophosphatasia, the condition upsets bone metabolism, blocking important minerals such as calcium from depositing in the skeleton. In the March 8, 2012, issue of the New England Journal of Medicine,...

2011-08-09 14:39:00

MONTREAL, Aug. 9, 2011 /PRNewswire/ -- Enobia Pharma Inc., a clinical stage biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it has raised US $40 million through the private placement of approximately 13,724,000 shares of its common stock to new pharmaceutical and financial investors. The proceeds will be used to fund the ongoing development of ENB-0040, Enobia's enzyme replacement therapy (ERT) for hypophosphatasia, a rare and...

2011-02-24 10:52:00

MONTREAL, Feb. 24, 2011 /PRNewswire/ -- Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia (HPP), a serious, rare metabolic bone disorder. Upon anticipated completion of the study later this year, Enobia will have collected safety and efficacy data for ENB-0040 in HPP patients of all ages. If approved, ENB-0040...

2011-01-10 15:30:00

SAN FRANCISCO, Jan. 10, 2011 /PRNewswire/ -- Enobia Pharma Inc., today announced that it has successfully completed a Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in juveniles with hypophosphatasia (HPP), a serious, rare metabolic bone disorder. The results were presented by Robert Heft, Ph.D., President and Chief Executive Officer of Enobia, at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco. The company announced today that...

2010-09-24 08:15:00

PRAGUE, Sept. 24 /PRNewswire/ -- Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages. Michael Whyte, MD, Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research...

2010-09-08 06:30:00

MONTREAL, Sept. 8 /PRNewswire/ -- Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages. Enobia announced today that it has been issued United States Patent No. 7,763,712 B2, providing robust...

2010-06-21 07:00:00

SAN DIEGO, June 21 /PRNewswire/ -- Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO...

2010-03-29 16:00:00

MONTREAL, March 29 /PRNewswire/ -- Enobia Pharma Inc. unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting. An update on the clinical program for ENB-0040, Enobia's investigational enzyme replacement therapy for HPP, was also presented at the meeting by Cheryl Rockman-Greenberg, MD, Medical Director, Child...

2009-11-03 07:01:00

MONTREAL, Nov. 3 /PRNewswire/ -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP. This study follows the recent presentation of positive Phase 2 data in infants, which showed that, in the majority of patients, six months of...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related